Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • seriousjust seriousjust Feb 26, 2013 12:05 AM Flag

    pipeline, beside pre-clinical

    vintafolide

    small lung, target phase II
    ovarian, proceed phase III
    breast, start phase II

    IND
    Description:

    EC0531 targets a chemotherapy drug to folate receptors over expressed on cancer cells. EC0531 targets a “super-potent” chemotherapy drug called tubulysin using our second-generation guidance system.
    Development Stage:

    EC0531 is currently in preclinical development.

    EC1069 targets a chemotherapy drug to PSMA receptors expressed on prostate cancer cells. EC1069 is constructed with a proprietary, high affinity targeting ligand that binds to PSMA together with a potent chemotherapy drug that inhibits microtubule activity.



    Development Stage:

    EC1069 is currently in preclinical development.

    EC0746 targets a highly potent anti-folate drug to activated macrophages overexpressing folate receptors.
    Development Stage:

    EC0746 is currently in preclinical development.

    EC0565 targets an immunosuppressive drug to folate receptors that are over-expressed on activated macrophages present within sites of inflammation. The drug is a very potent inhibitor of mTOR.

    Development Stage:

    EC0565 is currently in preclinical development.

    EC0371 is a folate-targeted, water soluble form of rapamycin that selectively inhibits mTOR activity in polycystic kidneys to reduce abnormal growth.

    Development Stage:

    EC0371 is currently in preclinical development.

    About 3 other Vintafolide threatments not sure yet, might be:

    - endometrial
    - 2 other ones

    Seen Merck's expiration in patents, might be in hurry, would not be surprised they make kind of a deal early wiht Tubulysin

    And of course, Endocyte will market EC 20 and other imaging diagnostics, ...!

    imfa

 
ECYT
3.13-0.01(-0.32%)Sep 23 4:00 PMEDT